Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. - Wikidata - awgldk - TriplyDB

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

http://www.wikidata.org/entity/Q33927755

about

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Vascularity of primary and metastatic renal cell carcinoma specimens.Estimation of renal cell carcinoma treatment effects from disease progression modeling Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.Role of randomized phase III trials in an era of effective targeted therapies.Current treatment considerations in metastatic renal cell carcinoma.Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment Management of metastatic kidney cancer in the era of personalized medicine.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery?Current Management Options in Metastatic Renal Cell Cancer.Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents.Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.The effect of information on preferences for treatments of metastatic renal cell carcinoma.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

P2860

Q34032864-43162D9B-D437-4710-9196-F58F44899683 Q34143407-3E0D2D78-37FE-48CA-A3FA-6897A900992D Q35080143-A5B7E506-8C95-452E-AEFA-A55560D2A8F6 Q35212949-979FE0EC-FF21-4D88-8E96-97B755AFEF06 Q35219246-FE270C0B-32AF-4A0C-A536-B958E1EDBA19 Q35623265-4AC4E397-DD01-4902-AEDF-1EBAB63F4276 Q35909843-2EF1FF4B-BA96-467D-9BA0-B5605C6F27C3 Q36349459-E43778D6-5BAB-498C-A4A0-E71D7CA4F92F Q36578610-68ABFDCF-9B09-4B3E-925E-5A1FD348F1FB Q37217573-BF71AB64-11CF-496D-A08F-8C0CD9682D93 Q37385255-1A54D70B-2FD9-4435-9D40-CDB0ED9AE587 Q37405933-7EE48EA1-B6C9-4E67-88E9-33D0BD241A84 Q37964935-5511C249-24EA-43FD-B225-692C68CD9311 Q37992827-6EB49F37-20F3-4B48-BB0D-5ADD6D12EC09 Q38025626-D2C21DEE-EF11-41D3-A8B1-3D7B550EE77E Q38180744-5A7EF851-1096-4FFB-81EE-1DE73F59D665 Q38233353-765385A2-E0D8-425F-BCEB-921E1E5045CB Q38259501-9F643B86-D94D-44CF-8833-F686000AC177 Q38261859-0102520D-A76F-429E-8CB9-14C116987C93 Q38531440-C2C37F7F-B3AD-4E6A-8D0A-A50E63825E79 Q38598277-4CC32737-F003-48CE-B15B-991DC6832DE8 Q38662325-E4FC0F41-56A5-4691-AACC-9D30B4119844 Q41111225-8F763CB4-0308-48A3-B1FB-A695F4B98A86 Q41145898-6A0A7AF0-1193-4C7F-867C-8FCC0B62DDAC Q42319246-504D9A28-E676-4F0B-B87D-C524BC08A9F2 Q42921489-5DE2AC49-569D-4C55-A753-DEB625BE7DD4 Q47158686-36A8B4B1-0758-40A8-A9F1-E58A9AB50430 Q47269814-B4122B25-F91C-4BE8-8D7F-D53CB934AD48 Q53136887-9960724D-21F4-4FBC-B4A6-4D51184E91BA Q53717818-72A34AFF-7C1D-494E-96C6-54C6B179493D

P2860

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

http://www.wikidata.org/entity/Q33927755

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Progression-free survival as a ...... contemporary targeted therapy.

@ast

Progression-free survival as a ...... contemporary targeted therapy.

@en

type

label

Progression-free survival as a ...... contemporary targeted therapy.

@ast

Progression-free survival as a ...... contemporary targeted therapy.

@en

prefLabel

Progression-free survival as a ...... contemporary targeted therapy.

@ast

Progression-free survival as a ...... contemporary targeted therapy.

@en

P1433

Q33927755-E4EA2FDB-F26E-42F0-B798-A34332AD7CE4

P1476

Q33927755-998F179E-FC55-4BEB-A4E1-1C5188780592

P2093

Q33927755-30482064-4CBC-452A-9575-AAD73D963AD3

Q33927755-3063E615-BD44-441B-BE07-5D9F3A08A99E

Q33927755-51250C9C-A022-48A7-A98E-0E646CF9DD36

Q33927755-576583D7-59BA-4409-A716-E9245E7DFFB3

Q33927755-57B51D90-7EAC-422F-88EF-7645D9EA399C

Q33927755-5DA43318-6C9C-4070-878E-0816E7D23510

Q33927755-80ADBA66-87C1-4264-A496-CBD5DD91F8DA

Q33927755-8BECE06F-15F5-48FC-B009-0BF2968F552B

Q33927755-FCC2B4BA-3441-4459-BD31-E286B46FB1BB

P2860

Q33927755-3FEF20C4-8CD2-42AC-A76D-2A8272FE4809

Q33927755-4C6C294E-E915-4428-BF1E-36ACE2FF6C13

Q33927755-5E0D0995-A6DE-488C-A77D-636B0DE619E3

Q33927755-75C6E7AA-7168-4006-9523-48651FC00D2B

Q33927755-887B7824-87F2-4998-BF05-8007E935119E

Q33927755-98B76D26-59A2-4A7F-B01E-1DC73E1C5FD1

Q33927755-A8F37B59-7573-41B3-AD17-D4DCD5AF8B83

Q33927755-B280A975-788D-43F5-8911-9E3CA1E8E364

Q33927755-BAC18F8B-2586-4525-A196-89DBB527F8A2

Q33927755-D0D007AA-CC69-4989-A941-31586E18D4FF

P304

Q33927755-B5DB985D-A17A-4576-8A96-AA4F1B951F85

P31

Q33927755-C2AD94B9-3D39-4974-B736-960770A7895F

P356

Q33927755-B7ED50AF-7D6D-49A4-BC29-D43CD7DE90A1

P407

Q33927755-D923112B-A134-446D-9463-85AFD4F5BEC7

P433

Q33927755-9D83CE0F-094C-4145-9233-44FFC326FE2C

P478

Q33927755-CAC7BB15-816D-4A15-8BB0-A837D75A26D5

P50

Q33927755-5CB9F659-62E0-404F-A9BD-CDDF24014213

Q33927755-9E13BEA6-4279-4AA4-B9EC-73583B087660

P577

Q33927755-27AF7E23-FFBA-4A2A-8A7F-52A257F8860A

P5875

Q33927755-5604960E-DFBF-47F2-B214-4E81A9CF691E

P698

Q33927755-FDB703D7-3023-41FC-8A7A-68C02A2B763A

P932

Q33927755-6F0C3F48-82CE-419B-A84D-AC9EE68953A7

P356

P1433

P1476

Progression-free survival as a ...... contemporary targeted therapy

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Christian Kollmannsberger

http://www.w3.org/2001/XMLSchema#string

Daniel Y C Heng

http://www.w3.org/2001/XMLSchema#string

Jennifer Knox

http://www.w3.org/2001/XMLSchema#string

Lori Wood

http://www.w3.org/2001/XMLSchema#string

Min-Han Tan

http://www.w3.org/2001/XMLSchema#string

Toni K Choueiri

http://www.w3.org/2001/XMLSchema#string

Ulka Vaishampayan

http://www.w3.org/2001/XMLSchema#string

Wanling Xie

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Detecting an overall survival benefit that is derived from progression-free survival

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

P304

2637-2642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25750

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Georg A. Bjarnason

P577

2010-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51204738

http://www.w3.org/2001/XMLSchema#string

P698

21656741

http://www.w3.org/2001/XMLSchema#string

P932

3856357

http://www.w3.org/2001/XMLSchema#string